Discovery of 3-({5-Chloro-1-[3-(methylsulfonyl)propyl]-1<i>H</i>-indol-2-yl}methyl)-1-(2,2,2-trifluoroethyl)-1,3-dihydro-2<i>H</i>-imidazo[4,5-<i>c</i>]pyridin-2-one (JNJ-53718678), a Potent and Orally Bioavailable Fusion Inhibitor of Respiratory Syncytial Virus
作者:Sandrine Vendeville、Abdellah Tahri、Lili Hu、Samuel Demin、Ludwig Cooymans、Ann Vos、Leen Kwanten、Joke Van den Berg、Michael B. Battles、Jason S. McLellan、Anil Koul、Pierre Raboisson、Dirk Roymans、Tim H. M. Jonckers
DOI:10.1021/acs.jmedchem.0c00226
日期:2020.8.13
Respiratory syncytial virus (RSV) is a seasonal virus that infects the lungs and airways of 64 million children and adults every year. It is a major cause of acute lower respiratory tract infection and is associated with significant morbidity and mortality. Despite the large medical and economic burden, treatment options for RSV-associated bronchiolitis and pneumonia are limited and mainly consist
呼吸道合胞病毒(RSV)是一种季节性病毒,每年感染6400万儿童和成人的肺和气道。它是急性下呼吸道感染的主要原因,并且与明显的发病率和死亡率有关。尽管医疗和经济负担沉重,但与RSV相关的细支气管炎和肺炎的治疗选择仍然有限,主要包括支持治疗。该出版物涵盖了导致鉴定JNJ-53718678的药物化学工作,JNJ-53718678是口服可生物利用的RSV抑制剂,在健康成人受试者的2a期挑战研究中显示出有效,目前正在住院婴儿和成人中进行评估。